CNTB Earnings Date: Nov 11, 2026 (Estimated) — Connect Biopharma Holdings Limited
NASDAQ · Healthcare · Biotechnology
Updated
When is CNTB's next earnings date?
Connect Biopharma Holdings Limited (CNTB) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 9:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.27 on revenue of $114,838.
How did CNTB do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Connect Biopharma Holdings Limited posted EPS of -$0.27 versus the -$0.31 estimate, a beat of 12.9%. Revenue was $2.8M against a $743,308 estimate. The stock's 1-day post-earnings move was +9.0%.
How much does CNTB stock move after earnings?
CNTB beat EPS estimates in 2 of its last 5 reported quarters. Over the last 8 reports the stock moved an average of 9.0% (up or down) in the day after earnings.
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.31 | -0.27 | +12.90% | $2.8M | ✅ Beat | +9.01% | +5.58% | -12.45% |
| 2026-05-12 | Q1 2026 | -0.28 | -0.34 | -21.43% | $169,000 | ❌ Miss | +14.53% | +1.71% | -11.11% |
| 2026-03-31 | Q4 2025 | -0.30 | -0.27 | +10.00% | $0 | ✅ Beat | +3.82% | +0.38% | -5.73% |
| 2025-11-12 | Q3 2025 | -0.27 | -0.31 | -14.81% | $16,000 | ❌ Miss | +5.92% | +69.08% | +59.87% |
| 2025-08-13 | Q2 2025 | -0.22 | -0.23 | -4.55% | $48,000 | ❌ Miss | +3.96% | -20.26% | -28.19% |
| 2025-03-31 | FY 2024 | — | -0.28 | — | $26.0M | — | -19.12% | -7.35% | +19.12% |
| 2024-09-05 | H1 2024 | — | 0.14 | — | $24.1M | — | +5.05% | +0.85% | +18.50% |
| 2024-04-16 | FY 2023 | — | -1.08 | — | $0 | — | -10.40% | -19.65% | +5.20% |
Showing last 8 quarters.